Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT00790582 · View on ClinicalTrials.gov ↗

Study Summary

This is a Phase II screening study of lithium carbonate in ALS. The purpose of this study is to find out if lithium carbonate is safe to be used in people with ALS and if it can slow the progression of the disease. Since there is no placebo in this study, all patients will be taking lithium carbonate.

Interventions

  • DRUG lithium carbonate

Study Locations (10)

California

  • UCLA Neuromuscular Research Center — Los Angeles
  • UC Irvine MDA/ALS & Neuromuscular Center — Orange
  • California Pacific Medical Center — San Francisco

Arizona

  • Mayo Clinic — Scottsdale

Kansas

  • Kansas University Medical Center — Kansas City

Missouri

  • Washington University Department of Neurology — St Louis

Oregon

  • Providence ALS Clinic — Portland

Pennsylvania

  • University of Pennsylvania Neurological Institute — Philadelphia

Texas

  • Methodist Neurological Institute — Houston

Utah

  • University of Utah Clinical Neurosciences Center — Salt Lake City

Trial Details

FieldValue
Enrollment Target 109 participants
Start Date 2008-05
Est. Completion 2010-03
Phase Phase 2

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00790582

The ClinicalTrials.gov registry entry for NCT00790582 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forbes Norris MDA/ALS Research Center, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention — of which lithium carbonate is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00790582 reports 10 study locations spanning 8 distinct geographic areas — top geographies include California, Arizona, Kansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00790582 about?

NCT00790582 is a clinical study titled "A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)". This is a Phase II screening study of lithium carbonate in ALS. The purpose of this study is to find out if lithium carbonate is safe to be used in people with ALS and if it can slow the progression of the disease. Since there is no placebo in this study, all patients will be taking lithium carbonat...

What is the current status of trial NCT00790582?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2008-05. Estimated completion is 2010-03.

What conditions does trial NCT00790582 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00790582?

The interventions under investigation include: lithium carbonate (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00790582?

This trial is sponsored by Forbes Norris MDA/ALS Research Center, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00790582 being conducted?

This trial has 10 study locations across Arizona, California, Kansas, Missouri, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial